Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 8/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24115355 | 0.92 | TLR2 (0.41) | KMT2ATLR2MDM2BMP1MDM4 | |
| SCHEMBL29508220 | 0.87 | KMT2A (0.36) | KMT2ATLR2MDM2BMP1MDM4 | |
| SCHEMBL21901416 | 0.83 | KMT2A (0.47) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL6514565 | 0.83 | KMT2A (0.49) | KMT2ATLR2 | |
| SCHEMBL29929002 | 0.82 | MDM2 (0.32) | KMT2ATLR2MDM2BMP1MDM4 | |
| SCHEMBL31469016 | 0.80 | KMT2A (0.46) | KMT2ATLR2 | |
| SCHEMBL14761684 | 0.78 | HPGD (0.33) | — | |
| SCHEMBL24263896 | 0.77 | ALDH1A1 (0.33) | KMT2A | |
| SCHEMBL24115316 | 0.76 | SLC6A1 (0.33) | — | |
| SCHEMBL27250464 | 0.76 | NPC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | KMT2A 1102/4885TLR2 301/4885MDM2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.